ReShape Lifesciences (RSLS, Financial) has announced an imminent 1-for-25 reverse stock split of its common shares, scheduled for May 9, 2025. This strategic move will consolidate every 25 shares into one. Despite this news, the stock faced a 21.34% dip in premarket trading, pricing at $0.35.
- ReShape Lifesciences plans a strategic 1-for-25 reverse stock split effective May 2025.
- The stock experienced a significant 21.34% decline in premarket trading.
- Analysts forecast a potential 194.12% upside with a $1.00 price target.
Wall Street Analysts Forecast
According to the one-year price targets provided by a single analyst, Reshape Lifesciences Inc (RSLS, Financial) holds an average target price of $1.00. Both the high and low estimates align at $1.00. This indicates a potential upside of 194.12% from the current trading price of $0.34. Investors seeking more detailed projections can visit the Reshape Lifesciences Inc (RSLS) Forecast page.
Brokerage Firm Recommendations
From the consensus recommendation compiled from one brokerage firm, Reshape Lifesciences Inc (RSLS, Financial) is currently rated an average of 3.0, signaling a "Hold" status. The rating scale ranges from 1 (Strong Buy) to 5 (Sell), with RSLS positioning in the middle, indicating a cautious outlook.
This strategic consolidation through a reverse stock split may be aimed at preventing delisting risks or improving the stock's market appeal. Investors should weigh this development alongside the analysts' "Hold" recommendation and price target for informed decision-making.
